Charles River Laboratories EBITDA 2010-2025 | CRL
Charles River Laboratories annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Charles River Laboratories EBITDA for the quarter ending June 30, 2025 was $0.220B, a 7.61% decline year-over-year.
- Charles River Laboratories EBITDA for the twelve months ending June 30, 2025 was $0.770B, a 13.8% decline year-over-year.
- Charles River Laboratories 2024 annual EBITDA was $0.804B, a 13.67% decline from 2023.
- Charles River Laboratories 2023 annual EBITDA was $0.931B, a 2.46% decline from 2022.
- Charles River Laboratories 2022 annual EBITDA was $0.955B, a 11.63% increase from 2021.
| Charles River Laboratories Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $804 |
| 2023 | $931 |
| 2022 | $955 |
| 2021 | $855 |
| 2020 | $668 |
| 2019 | $549 |
| 2018 | $493 |
| 2017 | $419 |
| 2016 | $364 |
| 2015 | $301 |
| 2014 | $276 |
| 2013 | $258 |
| 2012 | $265 |
| 2011 | $280 |
| 2010 | $120 |
| 2009 | $273 |
| Charles River Laboratories Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-06-30 | $220 |
| 2025-03-31 | $195 |
| 2024-12-31 | $149 |
| 2024-09-30 | $206 |
| 2024-06-30 | $238 |
| 2024-03-31 | $211 |
| 2023-12-31 | $213 |
| 2023-09-30 | $230 |
| 2023-06-30 | $243 |
| 2023-03-31 | $245 |
| 2022-12-31 | $241 |
| 2022-09-30 | $226 |
| 2022-06-30 | $264 |
| 2022-03-31 | $224 |
| 2021-12-31 | $240 |
| 2021-09-30 | $224 |
| 2021-06-30 | $206 |
| 2021-03-31 | $185 |
| 2020-12-31 | $190 |
| 2020-09-30 | $192 |
| 2020-06-30 | $134 |
| 2020-03-31 | $152 |
| 2019-12-31 | $161 |
| 2019-09-30 | $145 |
| 2019-06-30 | $129 |
| 2019-03-31 | $115 |
| 2018-12-31 | $144 |
| 2018-09-30 | $128 |
| 2018-06-30 | $120 |
| 2018-03-31 | $101 |
| 2017-12-31 | $96 |
| 2017-09-30 | $108 |
| 2017-06-30 | $113 |
| 2017-03-31 | $102 |
| 2016-12-31 | $105 |
| 2016-09-30 | $93 |
| 2016-06-30 | $90 |
| 2016-03-31 | $76 |
| 2015-12-31 | $76 |
| 2015-09-30 | $80 |
| 2015-06-30 | $80 |
| 2015-03-31 | $66 |
| 2014-12-31 | $67 |
| 2014-09-30 | $73 |
| 2014-06-30 | $76 |
| 2014-03-31 | $60 |
| 2013-12-31 | $54 |
| 2013-09-30 | $68 |
| 2013-06-30 | $68 |
| 2013-03-31 | $67 |
| 2012-12-31 | $60 |
| 2012-09-30 | $63 |
| 2012-06-30 | $74 |
| 2012-03-31 | $68 |
| 2011-12-31 | $67 |
| 2011-09-30 | $65 |
| 2011-06-30 | $80 |
| 2011-03-31 | $68 |
| 2010-12-31 | $-32 |
| 2010-09-30 | $39 |
| 2010-06-30 | $60 |
| 2010-03-31 | $54 |
| 2009-12-31 | $69 |
| 2009-09-30 | $69 |
| 2009-06-30 | $74 |
| 2009-03-31 | $62 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.965B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||